Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
Study Details
Study Description
Brief Summary
Ivermectin is currently being utilized by a number of physicians in the local area. My objective will be to enroll these patients at the time of their evaluation for COVID-19 infection and to follow their progress through their recovery.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Patients at local physician clinics as well as my own clinic will be enrolled at the time they are evaluated for having COVID-19. Patients enrollment will be voluntary and based upon their request for treatment with Ivermectin. These patients will be questioned on symptoms and the timing of those symptoms in detail. They will then be followed throughout their treatment course to evaluate their recovery experience. Detailed accounts of their symptoms and their resolution will be followed. The study patients will stop being followed when they are either admitted to the hospital or are deemed to be symptom free. Any other medications prescribed to the patients will also be tracked. Medical histories will be taken and documented to make comparisons at the end of the study. Those patients not requesting Ivermectin will also be followed for comparisons at a later date.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| COVID-19 patients treated with Ivermectin This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir. |
Drug: Ivermectin
Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
Other Names:
|
| COVID-19 patients declining Ivermectin and wanting traditional treatment This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir. |
Outcome Measures
Primary Outcome Measures
- Complete recovery from COVID-19 with resolution of symptoms [4-6 weeks per individual]
This group recovered completely from COVID-19 and remained an outpatient throughout the duration of their illness.
- Admission to a hospital for further advanced treatment [4-6 weeks per individual]
This group of patients was unable to recover at home and required hospital admission
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Between the ages of 12-110 years old
-
Has a recently completed COVID test
-
Symptomatic and seeking treatment
-
Willingness to participate and have follow-up
-
Able and willing to take medications and treatment suggestions from the physician
Exclusion Criteria: Lack of symptoms, uncertain of COVID-19 status, outside of age limits for treatment
-
No recent COVID test results
-
Asymptomatic, even if COVID positive
-
Outside of acceptable age range
-
Meets criteria for hospital admission
-
Unwilling to participate in trial study or have follow-up
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Patrick Robinson MD LLC | San Antonio | Florida | United States | 33576 |
Sponsors and Collaborators
- Patrick Robinson
Investigators
- Principal Investigator: Patrick r Robinson, MD, Patrick Robinson MD LLC
Study Documents (Full-Text)
None provided.More Information
Publications
- Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145. Review.
- Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12593-12608. doi: 10.26355/eurrev_202012_24057. Review.
- Ivermectin Treatment Study #1